Establishment Labs Holdings Inc (ESTA) Q3 2026 Earnings Call Highlights: US Revenue Surges
Establishment Labs (ESTA) reported Q3 2026 earnings with US revenue up 119%. CFO Sandra Harris expects 50-100 basis points of gross margin expansion in 2027. CEO Peter Caldini anticipates FDA approval for Motiva implants by late 2026 or early 2027. The company raised its full-year minimally invasive revenue expectation to over $40M. International markets are stable, with 16% growth in direct markets. The company is investing in its commercial team ahead of potential reconstruction approval.
How this was made
The 30-second read
Why it matters
Guidance on margins and FDA approval timeline could drive price movement.
Market read
The guidance and FDA timeline could influence biotech and medical‑device sector sentiment.
What to watch
Potential competition in reconstruction market and macro economic headwinds.
Background
Establishment Labs Holdings discussed Q3 2026 results and future outlook in its earnings call.
Ticker impact
Q3 adjusted gross margin of 70.8% and FDA approval for Motiva implants expected by end‑2026 or early‑2027 were disclosed.
likely upside as market prices in improved margins and FDA approval timeline
The earnings call provides fresh margin numbers and a clear FDA timeline, which can boost investor confidence.
Market effects
Positive outlook may lift other medical‑device and biotech stocks.
U.S. market could see modest gains in healthcare sector.
FDA timeline could affect global investors tracking medical‑device approvals.
Counterpoint
If FDA approval is delayed, the stock could face downside despite current guidance.
Key entities
- companyEstablishment Labs Holdings Inc
US-listed medical device manufacturer
